Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060695222> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2060695222 endingPage "654" @default.
- W2060695222 startingPage "649" @default.
- W2060695222 abstract "Macular choroidal neovascularization (CNV) is a serious complication of high myopia, compromising the visual prognosis in young patients. The purpose of this study was to evaluate the safety and efficacy of first-line intravitreal ranibizumab in the treatment of myopic CNV.We conducted a single-center prospective, consecutive, interventional study of patients with subfoveal or juxtafoveal CNV secondary to pathologic myopia (PM) treated with intravitreal injection of ranibizumab in the Beni-Messous University Hospital from January 2009 to April 2010. Best-corrected visual acuity (BCVA), fundus examination, optical coherence tomography (OCT), and fluorescein angiography (FA) were performed at baseline and monthly for all patients. Indications for retreatment were persistence or recurrence of the neovascular activity.The study included 40 eyes of 40 patients, 33 of whom were females (82.5%), with a mean age of 40.22 ± 10.81 years (range, 20-55 years), with visual acuity between 1/100 and 1/10. The mean spherical equivalent refractive error was -14.13 ± 4.65 diopters (range, -7 D to -23 D). The mean follow-up time was 8 months (range, 3-15 months). The mean number of intravitreal injections administered for each patient was 2.2 (range: 1-4). Follow-up ranged from 3 to 15 months (mean, 8 months). All patients maintained or improved their vision; the average gain in visual acuity was three lines (range: 1-9 lines). No injection complications or drug-related side effects were noted during the follow-up period.Intravitreal ranibizumab to treat CNV complicated by high myopia seems to be associated with an improvement in VA and good tolerance. This study confirms the efficacy of first-line anti-VEGF, in particular, ranibizumab in this indication.In this series of eyes with limited follow-up, intravitreal ranibizumab was a safe and effective treatment for CNV secondary to PM, resulting in functional and anatomic improvement." @default.
- W2060695222 created "2016-06-24" @default.
- W2060695222 creator A5013552709 @default.
- W2060695222 creator A5035826892 @default.
- W2060695222 creator A5075851988 @default.
- W2060695222 creator A5085340050 @default.
- W2060695222 creator A5085628385 @default.
- W2060695222 creator A5091563475 @default.
- W2060695222 date "2010-11-01" @default.
- W2060695222 modified "2023-09-27" @default.
- W2060695222 title "Néovaisseaux choroïdiens du myope fort : traitement par injection intravitréenne de ranibizumab" @default.
- W2060695222 cites W110906275 @default.
- W2060695222 cites W115342157 @default.
- W2060695222 cites W1977318048 @default.
- W2060695222 cites W1992041797 @default.
- W2060695222 cites W1992257311 @default.
- W2060695222 cites W1999555440 @default.
- W2060695222 cites W1999592084 @default.
- W2060695222 cites W1999809746 @default.
- W2060695222 cites W2029119558 @default.
- W2060695222 cites W2051258987 @default.
- W2060695222 cites W2072119754 @default.
- W2060695222 cites W2080591818 @default.
- W2060695222 cites W2081727392 @default.
- W2060695222 cites W2082606620 @default.
- W2060695222 cites W2085295554 @default.
- W2060695222 cites W2120866532 @default.
- W2060695222 cites W2154864259 @default.
- W2060695222 doi "https://doi.org/10.1016/j.jfo.2010.09.004" @default.
- W2060695222 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21047702" @default.
- W2060695222 hasPublicationYear "2010" @default.
- W2060695222 type Work @default.
- W2060695222 sameAs 2060695222 @default.
- W2060695222 citedByCount "8" @default.
- W2060695222 countsByYear W20606952222012 @default.
- W2060695222 countsByYear W20606952222013 @default.
- W2060695222 countsByYear W20606952222015 @default.
- W2060695222 countsByYear W20606952222017 @default.
- W2060695222 crossrefType "journal-article" @default.
- W2060695222 hasAuthorship W2060695222A5013552709 @default.
- W2060695222 hasAuthorship W2060695222A5035826892 @default.
- W2060695222 hasAuthorship W2060695222A5075851988 @default.
- W2060695222 hasAuthorship W2060695222A5085340050 @default.
- W2060695222 hasAuthorship W2060695222A5085628385 @default.
- W2060695222 hasAuthorship W2060695222A5091563475 @default.
- W2060695222 hasConcept C29456083 @default.
- W2060695222 hasConcept C71924100 @default.
- W2060695222 hasConceptScore W2060695222C29456083 @default.
- W2060695222 hasConceptScore W2060695222C71924100 @default.
- W2060695222 hasIssue "9" @default.
- W2060695222 hasLocation W20606952221 @default.
- W2060695222 hasLocation W20606952222 @default.
- W2060695222 hasOpenAccess W2060695222 @default.
- W2060695222 hasPrimaryLocation W20606952221 @default.
- W2060695222 hasRelatedWork W110906275 @default.
- W2060695222 hasRelatedWork W2047083844 @default.
- W2060695222 hasRelatedWork W233579014 @default.
- W2060695222 hasVolume "33" @default.
- W2060695222 isParatext "false" @default.
- W2060695222 isRetracted "false" @default.
- W2060695222 magId "2060695222" @default.
- W2060695222 workType "article" @default.